Interius BioTherapeutics, a Penn spinout co-founded by Saar Gill, PhD, Associate Professor of Medicine (Hematology-Oncology) at Penn Medicine, has received approval from the Human Research Ethics Committee (HREC) and Clinical Trial Notification (CTN) clearance from the Australian Therapeutic Goods Administration (TGA) to start a Phase 1 clinical trial for INT2104, its for B cell malignancies. INT2104 is a first-in-class iCAR therapy that specifically targets CD7-positive T and NK cells and delivers a CAR transgene to create effector CAR-T and CAR-NK cells in vivo , which target CD20-positive B cells for the treatment of B cell malignancies.
Interius intends to begin patient enrollment for the trial in the fourth quarter of 2024, which would allow delivery of key program milestones in early 2025.
Read more here.